More News

Scientists uncover genetic clues from tumour-prone reptile that could advance cancer research

Jim Cornall -
A new study, led by experts at the University of Nottingham in the UK, suggests a pet gecko with...

AI technology detects early warning signs of cerebrovascular disease at home

Jim Cornall -
Cerebrovascular disease can lead to serious aftereffects if treatment is delayed, but it is difficult to detect before symptoms...

Positive results from plantar fibromatosis trial

Jim Cornall -
Keenova Therapeutics plc has announced positive results from its phase 3 clinical trial of XIAFLEX (collagenase clostridium histolyticum) for...

KAIST brings microbial cell factories one step closer

Jim Cornall -
The era of biomanufacturing, where microbes and not petroleum produce chemical products, is one step closer. A KAIST research team...

$18m investment in malaria, TB and NTD projects

Jim Cornall -
The Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately $18m in six R&D projects...

Anticancer “nanoswitch” technology developed

Jim Cornall -
A research team led by Yoosoo Yang (Department of Integrative Biotechnology) at SKKU, in collaboration with the Korea Institute...

Epigenetic mapping provides deeper insight into leukaemia

Jim Cornall -
Researchers at Karolinska Institutet in Sweden and Kyoto University in Japan have identified new subgroups of the blood cancer...

Base to Base biotech podcast 67: Synthetic DNA and crossing the blood-brain barrier

Jim Cornall -
This week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at...

New CRISPR method makes it possible to control protein production in cells

Jim Cornall -
The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specialises, or...

KAIST enables DNA synthesis using only temperature

Jim Cornall -
"Complex chemical processes are essential for making DNA." This long-held assumption in the field of biotechnology has been overturned by...

Novartis to acquire Myricx Bio

Jim Cornall -
Novartis has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new...

New approach to rare disease drug development yields first research results

Jim Cornall -
A team of scientists and business professionals at Queen Mary University of London have made a significant step towards...

PFAS in medicines can often be replaced with alternatives

Jim Cornall -
Certain medicines contain per- and polyfluorinated alkyl compounds, known as PFAS, which are causing increasing environmental harm due to...

Polyomaviruses: new approaches to prevention and treatment

Jim Cornall -
In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease. Now,...

ten23 health obtains Swissmedic licences for Basel and Visp facilities

Jim Cornall -
ten23 health, a global contract development and manufacturing organisation (CDMO) focused on sterile and biologic drug products, today announced...

SK bioscience launches initiative to reduce uncertainty in vaccine-development decisions

Jim Cornall -
SK bioscience will lead the Research Optimization & Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical...

Human embryo gene-correction research approved

Jim Cornall -
Origin Genomics has secured Institutional Review Board (IRB) approval for its human embryo gene-correction research protocol and has launched...

New immunotherapy strategy targets aggressive brain tumours and their fuel

Jim Cornall -
Researchers at McMaster University in Canada have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain...

New tool gives scientists clearer view of DNA regulation

Jim Cornall -
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at NUS have developed a new method that allows...

Base to Base biotech podcast 66: The future of clinical trials and breakthroughs in molecular testing

Jim Cornall -
This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies,...

Fast Track Designation for epidermolysis bullosa simplex treatment

Jim Cornall -
BioMendics, LLC, a clinical-stage biotechnology company developing therapies for rare genetic skin disorders, has announced that the U.S. Food...